These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 28195647)

  • 21. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
    Sjödahl G; Lövgren K; Lauss M; Chebil G; Patschan O; Gudjonsson S; Månsson W; Fernö M; Leandersson K; Lindgren D; Liedberg F; Höglund M
    Urol Oncol; 2014 Aug; 32(6):791-7. PubMed ID: 24794251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic subtypes of invasive bladder cancer.
    McConkey DJ; Choi W; Dinney CP
    Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
    Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
    J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying distinct classes of bladder carcinoma using microarrays.
    Dyrskjøt L; Thykjaer T; Kruhøffer M; Jensen JL; Marcussen N; Hamilton-Dutoit S; Wolf H; Orntoft TF
    Nat Genet; 2003 Jan; 33(1):90-6. PubMed ID: 12469123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.
    Berndt A; Anger K; Richter P; Borsi L; Brack S; Silacci M; Franz M; Wunderlich H; Gajda M; Zardi L; Neri D; Kosmehl H
    J Cancer Res Clin Oncol; 2006 Aug; 132(8):537-46. PubMed ID: 16788848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p63 gene expression study and early bladder carcinogenesis.
    Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
    Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological determinants of bladder cancer gene expression subtypes.
    Aine M; Eriksson P; Liedberg F; Sjödahl G; Höglund M
    Sci Rep; 2015 Jun; 5():10957. PubMed ID: 26051783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bladder cancer.
    Mhawech-Fauceglia P; Ali L; Cheney RT; Groth J; Herrmann FR
    J Clin Pathol; 2009 Aug; 62(8):710-4. PubMed ID: 19638542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
    Lindgren D; Frigyesi A; Gudjonsson S; Sjödahl G; Hallden C; Chebil G; Veerla S; Ryden T; Månsson W; Liedberg F; Höglund M
    Cancer Res; 2010 May; 70(9):3463-72. PubMed ID: 20406976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual role of TGFBR3 in bladder cancer.
    Liu XL; Xiao K; Xue B; Yang D; Lei Z; Shan Y; Zhang HT
    Oncol Rep; 2013 Sep; 30(3):1301-8. PubMed ID: 23835618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
    Biton A; Bernard-Pierrot I; Lou Y; Krucker C; Chapeaublanc E; Rubio-Pérez C; López-Bigas N; Kamoun A; Neuzillet Y; Gestraud P; Grieco L; Rebouissou S; de Reyniès A; Benhamou S; Lebret T; Southgate J; Barillot E; Allory Y; Zinovyev A; Radvanyi F
    Cell Rep; 2014 Nov; 9(4):1235-45. PubMed ID: 25456126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward a molecular pathologic classification of urothelial carcinoma.
    Sjödahl G; Lövgren K; Lauss M; Patschan O; Gudjonsson S; Chebil G; Aine M; Eriksson P; Månsson W; Lindgren D; Fernö M; Liedberg F; Höglund M
    Am J Pathol; 2013 Sep; 183(3):681-91. PubMed ID: 23827819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
    Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder.
    Adam RM; DeGraff DJ
    Urol Oncol; 2015 Oct; 33(10):444-50. PubMed ID: 26254697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer.
    Tan TZ; Heong V; Ye J; Lim D; Low J; Choolani M; Scott C; Tan DSP; Huang RY
    J Pathol; 2019 Mar; 247(3):305-319. PubMed ID: 30374975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bladder cancer outcome and subtype classification by gene expression.
    Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
    Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients.
    Rady M; Mostageer M; Rohde J; Zaghloul A; Knüchel-Clarke R; Saad S; Attia D; Mahran L; Spahn-Langguth H
    Oncol Rep; 2017 Jul; 38(1):551-560. PubMed ID: 28586062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells.
    Heubach J; Monsior J; Deenen R; Niegisch G; Szarvas T; Niedworok C; Schulz WA; Hoffmann MJ
    Mol Cancer; 2015 May; 14():108. PubMed ID: 25994132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.